
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Hit Discovery</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header><h1>Hit Discovery</h1></header>
  <nav><a href="index.html">Back to Home</a></nav>

<main>
    <section>
      <h2>What is Hit Discovery?</h2>
      <p>Hit discovery is the process of identifying chemical compounds (hits) that show desirable activity against a validated biological target. These hits serve as starting points for further optimization in the drug development pipeline.</p>
    </section>

    <section>
      <h2>Basic Concepts</h2>
      <ul>
        <li><strong>Hit:</strong> A compound that demonstrates measurable activity in a biological assay.</li>
        <li><strong>Assay:</strong> An experimental setup to test compound activity, often in vitro.</li>
        <li><strong>Library:</strong> A collection of compounds screened for activity.</li>
      </ul>
    </section>

    <section>
      <h2>Screening Methods</h2>
      <ul>
        <li><strong>High-Throughput Screening (HTS):</strong> Automated testing of thousands to millions of compounds.</li>
        <li><strong>Fragment-Based Screening:</strong> Uses small chemical fragments to identify binding interactions.</li>
        <li><strong>Virtual Screening:</strong> Computational methods to predict active compounds using molecular docking and AI.</li>
        <li><strong>Phenotypic Screening:</strong> Identifies hits based on observable cellular or organismal responses.</li>
      </ul>
    </section>

    <section>
      <h2>Technologies and Tools</h2>
      <ul>
        <li>Robotic liquid handling systems</li>
        <li>Microplate readers and imaging systems</li>
        <li>Computational docking software (e.g., AutoDock, Glide)</li>
        <li>Machine learning models for activity prediction</li>
      </ul>
    </section>

    <section>
      <h2>Hit Validation</h2>
      <ul>
        <li>Re-testing hits in confirmatory assays</li>
        <li>Determining potency (IC50, EC50)</li>
        <li>Assessing selectivity and toxicity</li>
        <li>Structure-activity relationship (SAR) analysis</li>
      </ul>
    </section>

    <section>
      <h2>Challenges in Hit Discovery</h2>
      <ul>
        <li>False positives and assay artifacts</li>
        <li>Low hit rates in complex targets</li>
        <li>Compound solubility and stability issues</li>
        <li>Data management and reproducibility</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Examples</h2>
      <ul>
        <li><strong>Kinase inhibitors:</strong> HTS campaigns led to discovery of hits for cancer therapy.</li>
        <li><strong>Antiviral agents:</strong> Virtual screening identified hits against SARS-CoV-2 protease.</li>
        <li><strong>Antibiotics:</strong> Phenotypic screens revealed novel hits against resistant bacteria.</li>
      </ul>
    </section>

    <section>
      <h2>Future Directions</h2>
      <ul>
        <li>AI-driven hit prediction and de novo design</li>
        <li>Integration of multi-omics data for hit prioritization</li>
        <li>Use of organoids and 3D cell cultures in screening</li>
        <li>Cloud-based platforms for collaborative screening</li>
      </ul>
    </section>
  </main>

  <footer><p>&copy; 2025 Drug Discovery Knowledge Base</p></footer>
</body>
</html>
